Simon两阶段无效性试验在早期帕金森病中的可行性:基于PRECEPT和DATATOP试验数据集的分析
本研究对PRECEPT和DATATOP两项早期帕金森病随机对照试验的患者水平数据进行事后分析,探索Simon两阶段无效性试验设计的可行性。分析提出以统一帕金森病评定量表运动评分恶化5分作为主要结局、随访12个月,模拟所需样本量低于200例。作者认为该设计在帕金森病中可行,可能加速早期帕金森病 promising 治疗的发现。
要点
- 基于PRECEPT和DATATOP数据,Simon两阶段无效性试验在帕金森病中可行。
- 作者提出以UPDRS运动评分恶化5分为主要结局、随访12个月。
- 模拟显示所需样本量低于200例。
核心结论
- 基于DATATOP和PRECEPT分析,采用Simon两阶段方法的2期临床试验在帕金森病中可行,可能加速早期帕金森病 promising 治疗的发现。
研究设计与样本
- 本研究为对早期帕金森病DATATOP和PRECEPT两项随机对照试验的原始患者水平数据的事后分析。
- PRECEPT纳入806例参与者(平均年龄59.7岁,SD 10.3,64.4%为男性),DATATOP纳入800例参与者(平均年龄61.1岁,SD 9.5,64.4%为男性)。
- 分析使用描述性统计、生存分析和二元逻辑回归探索UPDRS运动评分变化阈值、随访时长、纳入排除标准及Simon两阶段无效性试验的预计样本量。
- 还进行bootstrapping实验以展示Simon两阶段无效性设计识别司来吉兰为非无效和生育酚为无效的能力。
主要发现
- 分析提示采用Simon两阶段方法的无效性试验在帕金森病中可行。
- 作者提出以UPDRS运动评分恶化5分作为主要结局指标,随访时长为12个月。
- 基于这些数据的试验模拟提示此类临床试验所需样本量低于200例参与者。
关键数值与推荐
- 作者提出以UPDRS运动评分恶化5分作为主要结局指标。
- 作者提出随访时长为12个月。
- 基于这些数据的试验模拟提示所需样本量低于200例参与者。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Disease-modifying treatments (DMTs) are a major unmet need in Parkinson disease (PD). To date, trials investigating DMT candidates in PD most often used a randomized controlled trial (RCT) design. Unfortunately, RCTs to date have not led to a breakthrough, in part because of the large sample sizes and length of follow-up required. In the interest of testing DMT candidates in a more efficient manner, it may be worthwhile to perform futility trials, which are smaller clinical trials that have originally been developed as phase 2 trials in oncology and more recently been used in progressive multiple sclerosis. In this investigation, we used original, patient-level data from DATATOP and PRECEPT, 2 large RCTs in early PD, to explore the feasibility of using the Simon 2-Stage futility trial design in early PD. METHODS: This is a post hoc analysis of original, patient-level data from the DATATOP and PRECEPT RCTs in early PD. In our analyses, we use descriptive statistics, survival analysis, and binary logistic regression to explore thresholds of change in the Unified Parkinson Disease Rating Scale (UPDRS) motor score as the primary outcome measure, length of follow-up, inclusion and exclusion criteria, and projected sample sizes for Simon 2-Stage futility trials in early PD. We also performed bootstrapping experiments to illustrate the ability of trials using the Simon 2-Stage futility design to identify selegiline as nonfutile and tocopherol as futile. RESULTS: PRECEPT included 806 participants (mean age 59.7 years, SD 10.3, 64.4% male), and DATATOP included 800 participants (mean age 61.1 years, SD 9.5, 64.4% male). Our analyses suggest that futility trials using the Simon 2-Stage methodology are feasible in PD. We propose a 5-point worsening on the UPDRS motor score as the primary outcome measure and a length of follow-up of 12 months. Trial simulations based on these data suggest the required sample size for such clinical trials to be lower than 200 participants. DISCUSSION: Based on our analysis of DATATOP and PRECEPT, phase 2 clinical trials using the Simon 2-Stage methodology are feasible in PD and may offer an opportunity to expedite the discovery of promising treatments in early PD.
引用
- Koch MW, Kalia LV, Sarna JR, et al. Feasibility of Simon 2-Stage Futility Trials in Early Parkinson Disease: Analysis of the PRECEPT and DATATOP Trial Datasets. Neurology. 2024. PMID: 39642339. doi:10.1212/WNL.0000000000210079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。